Second Clinical Trial Getting Underway for PathMaker's Non-Invasive ALS Treatment Platform. BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. ("PathMaker”), ...
In a real-world study, In the end, researchers compared 395 ALS patients who'd been given Radicava against 395 matched ...
Roy Woodlief, center, poses with Wake County Sheriff Donnie Harrison and Terry Putnam after Woodlief graduated the academy ...
Competing in a marathon could be considered quite the task for some, but not for one Amyotrophic Lateral Sclerosis (ALS) ...
Barbara Goodfriend, 83, opted for medical aid in dying after being diagnosed with ALS. The New Jersey widow ended her life in ...
Masitinib is an oral inhibitor of tyrosine kinases, enzymes important for immune cells thought to drive ALS inflammation and ...
Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up ...
Western student applying occupational therapy to her ALS experience to help other families manage their daily lives with physical or cognitive impairment.
A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.
Qure (QURE) announced that the Independent Data Monitoring Committee for EPISOD1, uniQure’s Phase I/II clinical trial of AMT-162, an ...
MAID is currently legal in 10 states and Washington, D.C., but eight other states are considering similar laws this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback